Overview: Anti-Thyroid Peroxidase (TPO) IgG Antibody Rapid TestIntroduction: The Anti-Thyroid Peroxidase (TPO) IgG Antibody Rapid Test is a diagnostic tool designed to detect TPO IgG antibodies in serum, whole blood, or saliva samples, facilitating the screening of thyroid autoimmune disorders. These autoantibodies are associated with Hashimoto's thyroiditis and Graves' disease, presenting with fatigue, weight changes, and severe complications like hypothyroidism or hyperthyroidism if untreated, particularly in women or those with family history. Per the 2023 American Thyroid Association guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with reasonable sensitivity and specificity, making it a valuable tool for initial screening in endocrinology clinics. This rapid diagnostic falls under immunology and targets individuals with thyroid symptoms, addressing the challenge of early detection to guide levothyroxine or antithyroid therapy. With morbidity rates elevated due to undiagnosed thyroid dysfunction, the test supports public health efforts by enabling early identification, facilitating specialist referrals, and reducing metabolic complications. Its multi-sample capability enhances its utility.Other Names: TPO IgG Rapid Test.FDA Status: FDA approved, CLIA certified for immunology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Roche, this test advanced TPO detection, providing a rapid alternative to ELISA.Purpose: The test screens for TPO IgG to guide thyroid autoimmune disorder diagnosis, assess disease risk, and inform treatment and prevention strategies.Test Parameters: Presence of TPO IgG Antibody, detected with reasonable specificity to indicate autoimmune activity, typically detectable in serum or blood during active thyroid disease.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report fatigue, weight changes, or neck swelling.Specimen: Serum 2-5 mL, Whole Blood 2-5 mL, Saliva 1-2 mL, collected using sterile SST or EDTA tubes/containers, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve antibody integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may degrade antibodies, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on fatigue, weight changes, goiter, or prior thyroid conditions, as well as any family history of thyroid disease or recent infections.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated thyroid disorders including heart disease, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent thyroid injury can affect results. Correlation with TSH or imaging is recommended to confirm findings.Clinical Significance: A positive result indicates possible thyroid autoimmune disorder, necessitating further investigation like TSH levels or endocrinology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled during inactive disease.Specialist Consultation: Endocrinologists should be consulted for case management, treatment planning, and coordination with thyroid disease programs.Additional Supporting Tests: TSH, T4, or TPO titer for confirmation.Test Limitations: The test may produce false positives in other autoimmune conditions or false negatives in early disease, requiring a comprehensive diagnostic approach that includes clinical correlation.References: ATA Guidelines 2023, Thyroid 2024, Journal of Immunology 2025.